Your browser doesn't support javascript.
loading
Resistance to targeted therapies: delving into FLT3 and IDH.
Desikan, Sai Prasad; Daver, Naval; DiNardo, Courtney; Kadia, Tapan; Konopleva, Marina; Ravandi, Farhad.
Affiliation
  • Desikan SP; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, USA.
  • Daver N; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, USA.
  • DiNardo C; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, USA.
  • Kadia T; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, USA.
  • Konopleva M; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, USA.
  • Ravandi F; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, USA. fravandi@mdanderson.org.
Blood Cancer J ; 12(6): 91, 2022 06 09.
Article in En | MEDLINE | ID: mdl-35680852
ABSTRACT
Recent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impacting alternate pathways, and changes in the microenvironment. Here we review the role of these proteins in leukemogenesis, their respective inhibitors, mechanisms of resistance, and briefly ongoing studies aimed at overcoming resistance.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myeloid, Acute Limits: Humans Language: En Journal: Blood Cancer J Year: 2022 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myeloid, Acute Limits: Humans Language: En Journal: Blood Cancer J Year: 2022 Type: Article Affiliation country: United States